A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-15 and is reviewed periodically as new material appears.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
YAN is a measurement of the primary organic (free amino acids) and inorganic (ammonia and ammonium) sources of nitrogen that can be assimilated by S. cerevisiae. There are several nitrogenous compounds found in must and wine including peptides, larger proteins, amides, biogenic amines, pyridines, purines and nucleic acids but these cannot be directly used by yeast for metabolism. Taken together, the total nitrogen content of grape must can range from 60 to 2400 mg of nitrogen per liter, however not all of this nitrogen will be assimilable. The lack of protease enzymes, which break down larger peptides into smaller components, that can work outside the cell, limits the size of the molecules that yeast can use as a source for nitrogen. The amount of YAN that winemakers will see in their grape musts depends on a number of components including grape variety, rootstock, vineyard soils and viticultural practices (such as the use of fertilizers and canopy management) as well as the climate conditions of particular vintages. Infections by mold, such as Botrytis cinerea (known as noble rot when it is desired) can reduce the amino acid content of grape must by as much as 61%. Some regions are noted for having low YAN such as Washington State which during a typical vintage will have 90% of tested must below 400 mg N/L and nearly a quarter be below 150 mg N/L. In the vineyard, nitrogen is taken up by the grapevine as nitrate (NO3−), ammonium or urea which gets reduced into ammonia.
These models have a prominent bonnet scoop. At about the same time a all-wheel-drive model was introduced in Japan, either with a 1.6-litre petrol or the Isuzu turbo-diesel. The 4WD cars can be easily identified by having been equipped with the federalized front (but not rear) bumper, including side marker lights. The rare North American ES model came with the Miata (NA)'s 1.8-litre twin-cam engine (though the internals were not entirely the same), all-wheel disc brakes, and dual stabilizer bars. The same car went on sale in Australia in the second half of 1994 with a fully featured BP-ZE engine. The Protegé became classified as a "compact car" for the 1995 model year in North America. A version with Mazdaspeed accessories was released in Japan and Philippines. It came equipped with Mazdaspeed wrap around bodykit, Mazdaspeed rear spoiler, Momo steering wheel, 15-inch Rota Astral wheels wrapped in 195/55R15 Bridgestone Potenza RE01 tires, Mazdaspeed strut tower bar, Eibach springs, gas-charged shock absorbers, swaybars and Mazdaspeed exhaust made by Yumex. The Familia/Protegé/323 was facelifted in October 1996, with a newer somewhat calmer style. This generation was discontinued in 1998 in most markets, but continued to be available in some markets until 1999 or 2000. For example, the 3-door hatchback was available in Europe until October 2000.
=== Ba–Bee === David Baker (b. 1962). American biochemist and computational biologist at the University of Washington, who studies methods to predict and design the three-dimensional structures of proteins. Nobel Prize in chemistry, 2024. Tania A. Baker (PhD 1988). American biochemist at MIT, who has studied transposons and enzymes that catalyse protein unfolding. Member Natl. Acad. Sci. USA. Clinton Ballou (1923–2021). American biochemist at UC Berkeley, whose research focused on the metabolism of carbohydrates and the structures of microbial cell walls. Member Natl. Acad. Sci. USA. Horace Barker (1907–2000). American biochemist and microbiologist at UC Berkeley. Member Natl. Acad. Sci. USA. David Bartel (PhD 1993). American biochemist at MIT, known for work on microRNA biology. Member Natl. Acad. Sci. USA. Bonnie Bassler (b. 1962). American molecular biologist at Princeton, known for studies of quorum sensing, and the idea that disruption of chemical signalling can be used as an antimicrobial therapy. Member Natl. Acad. Sci. USA. Philip A. Beachy (b. 1958). American biochemist at Stanford, known for studies to understand the molecular mechanisms behind the growth of multicellular embryos, especially the role of the Hedgehog signalling pathway. Member Natl. Acad. Sci. USA. Jon Beckwith (b. 1935). American microbiologist and geneticist at Harvard who made important contributions to the study of bacterial genetics. Member Natl. Acad. Sci. USA.
A board foot is a United States and Canadian unit of approximate volume, used for lumber. It is equivalent to 1 inch × 1 foot × 1 foot (144 in3 or 2,360 cm3). It is also found in the unit of density pounds per board foot. In Australia and New Zealand the terms super foot or superficial foot were formerly used for this unit. The exact volume of wood specified is variable and depends on the type of lumber. For planed lumber the dimensions used to calculate board feet are nominal dimensions, which are larger than the actual size of the planed boards. See Dimensional lumber for more information on this.
=== Cognitive symptoms === An obsession with counting calories and monitoring contents of food Preoccupation with food, recipes, or cooking; may cook elaborate dinners for others, but not eat the food themselves or consume a very small portion; can do so in order to distract others from noticing the condition Admiration of thinner people Thoughts of being fat or not thin enough An altered mental representation of one's body Impaired theory of mind, exacerbated by lower BMI and depression Memory impairment Difficulty in abstract thinking and problem solving Rigid and inflexible thinking Poor self-esteem Hypercriticism and perfectionism
Sources: en.wikipedia.org
In a meeting of the Quadrilateral Security Dialogue on the implications of the 2022 Russian invasion of Ukraine for the region, President Biden noted India's abstention, saying that most global allies were united against Russia. Speaking to the US Senate Foreign Relations Committee, US diplomat Donald Lu said the Biden administration was still considering sanctions against India over its S-400 deal with Russia, and its abstention at the UN. However, the Biden administration has ruled out secondary sanctions against India for its considerable oil imports or defence engagement from Russia.
== Adverse effects == The most common side effects include headache, insomnia, sleepiness, parkinsonism (effects similar to Parkinson's disease such as shaking, muscle stiffness and slow movement), dystonia (involuntary muscle contractions), tremor (shaking), dizziness, akathisia (restlessness), agitation, anxiety, depression, weight gain, nausea, vomiting, constipation, dyspepsia (heartburn), diarrhea, dry mouth, tiredness, toothache, muscle and bone pain, back pain, asthenia (weakness), tachycardia (increased heart rate), high blood pressure, prolonged QT interval (an alteration of the electrical activity of the heart), upper respiratory tract infection (nose and throat infections) and cough. A 2020 pharmacovigilance study using the Korean Adverse Event Reporting System (KAERS) compared safety signals for paliperidone with those of other atypical antipsychotics. The analysis found that paliperidone was disproportionately associated with hyperprolactinemia‑related events (galactorrhea, amenorrhea, gynecomastia), weight increase, and metabolic disturbances. The authors concluded that the real‑world safety profile of paliperidone warrants continued monitoring, particularly for endocrine and metabolic adverse effects. A 2023 study found that paliperidone may worsen verbal learning and memory compared to placebo in the early months of psychosis treatment. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.
A technique called osteo-odonto-keratoprosthesis (OOKP) uses a staged operation on those who have developed corneal blindness in which a laminated tooth is transplanted to serve as a support for an artificial optical cylinder.
Deathmatch includes some notable features such as instant respawn; weapons that have specific spawn points; and special abilities (sprint, flashlight, etc.). The aim of the deathmatch is simple: the player must kill other players to score points. If the player accidentally self-kills, they lose points. If a player is killed, they will respawn with 100 health points and the default spawn weapons, but will lose all the weapons and ammunition acquired before being killed. The game is server based and each server contains different rules for each round therefore there is no default time limit or kill limit for each round.
== Clinical significance == Mice with mutant carboxypeptidase E, Cpefat, display endocrine disorders like obesity and infertility. In some strains of mice, the fat mutation also causes hyperproinsulinemia in adult male mice, but this is not found in all strains of mice. The obesity and infertility in the Cpefat mice develop with age; young mice (<8 weeks of age) are fertile and have normal body weight. Peptide processing in Cpefat mice is impaired, with a large accumulation of peptides with C-terminal lysine and/or arginine extensions. Levels of the mature forms of peptides are generally reduced in these mice, but not eliminated. It is thought that a related enzyme (carboxypeptidase D) also contributes to neuropeptide processing and gives rise to the mature peptides in the Cpefat mice. Mutations in the CPE gene are not common within the human population, but have been identified. One patient with extreme obesity (Body Mass Index >50) was found to have a mutation that deleted nearly the entire CPE gene. This patient had intellectual disability (inability to read or write) and had abnormal glucose homeostasis, similar to mice lacking CPE activity. In obesity, high levels of circulating free fatty acids have been reported to cause a decrease in the amount of carboxypeptidase E protein in pancreatic beta-cells, leading to beta-cell dysfunction (hyperproinsulinemia) and increased beta-cell apoptosis (via an increase in ER stress).
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.